Financial results for the period ended September 30, 2025
As filed · Fortis Healthcare Limited has submitted to the Exchange, the financial results for the period ended September 30, 2025.
What happened
FactFortis Healthcare Limited has submitted to the Exchange, the financial results for the period ended September 30, 2025. considered and approved the Un-Audited Standalone and Consolidated Financial Results of the Company for the. Accordingly, please find enclosed herewith Un-Audited Standalone and Consolidated Financial Results of the.
Why it matters
CapitSignal interpretationReported results are the point at which prior management commitments become checkable against audited or reviewed numbers.
What management said before
Prior statements by this company that CapitSignal has recorded changing.
Capex
RevisedWe recorded a gross addition of 7 labs -- 7 new labs and 200-plus new customer touchpoints during this quarter, reflecting our continued focus on strengthening presence and accessibility across geographies.
We launched 19 new tests this quarter, expanding our capabilities in oncology, infectious diseases and autoimmune diagnostics.
Change
FactImplication
CapitSignal interpretationWatch next
Fact- Margin trend against the prior period
- Cash from operations against reported profit
- Whether prior guidance is reaffirmed
- Company acquires People Tree Hospital Yeshwanthpur for INR 430 Crs; plans to scale up infrastructure with a fu (management committed by FY27)
- Fortis plans investment of ~INR 840 Crs for 300+ beds in Bengaluru (management committed by FY27)
Evidence
- Fortis Healthcare Limited has informed regarding the Un-audited Financial Results for the Quarter and half Year ended September 30, 2025.(opens the original filing in a new tab)
- Earlier statement · Q2 FY26
- Latest statement · Q2 FY26
- Earlier statement · Q1 FY27
How CapitSignal classified this
- Reasoning:
- RESULTS base 68; +4 corroborating keywords; matched on subject
- Matched on:
- the filing's own subject line
- Confidence in the event type:
- 90%